Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
anti-EGFR-IL-dox in advanced EGFR+ TNBC
NCT02833766Phase 2Terminated
- Sponsor
- Swiss Group for Clinical Cancer Research
- Start
- Oct 2016
- Primary completion
- Oct 2020
- Countries
- 1
01
Overview
A Phase 2 trial of anti-EGFR immunoliposomes loaded with doxorubicin in triple negative breast cancer (TNBC), sponsored by Swiss Group for Clinical Cancer Research. Started Oct 2016; status: terminated.
02
Drugs
anti-EGFR immunoliposomes loaded with doxorubicin
03
Conditions
triple negative breast cancer (TNBC)
Beyond the preview
Go deeper on NCT02833766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02833766.